| (Values in U.S. Thousands) | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 |
| Sales | 2,470 | 4,810 | 50 | 0 | 0 |
| Sales Growth | -48.65% | +9,519.81% | unch | unch | unch |
| Net Income | -21,870 | -10,780 | -3,100 | -5,310 | -4,180 |
| Net Income Growth | -102.88% | -247.74% | +41.62% | -27.03% | -1.46% |
Aceragen Inc (ACGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aceragen Inc. is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. Its portfolio includes late-stage programs based on well-established biological principles. Aceragen Inc., formerly known as Idera Pharmaceuticals Inc., is based in DURHAM, N.C.
Fiscal Year End Date: 12/31